FFCD - Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: the SAMCO-PRODIGE 54 randomized phase II trial

Avelumab versus standard second-line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: the SAMCO-PRODIGE 54 randomized phase II trial

Auteurs

Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, Jérémie Bez, Clémence Toullec, Christophe Borg, Violaine Randrian, Ludovic Evesque, Stéphane Corbinais, Hervé Perrier, Bruno Buecher, Frederic Di Fiore, Claire Gallois, Jean Francois Emile, Côme Lepage, Farid Elhajbi, David Tougeron

Journal / Conférence

JAMA Oncology

Type de publication

Article

Etude

PRODIGE 54 - SAMCO

Localisation

Colorectal